Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

BrainStorm Cell Therapeutics Updates On NurOwn Stem Cell Therapy For ALS

Author: Benzinga Newsdesk | July 24, 2024 08:33am

CMC FDA Questions Resolved, PIIIb Rollout Begins, $4M Raised, Commercialization Team In Place; Signed CRO And Lined Up Commercial Manufacturer; Despite ~5% Value Range Reduction Due To Dilution, Investment Hypothesis Remains >10x Return; Exploring Non-Dilutive Grant Funds

Posted In: BCLI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist